FDA Approves LYTENAVA (BLA761320) from Outlook Therapeutics
The FDA has approved LYTENAVA (BLA761320), a new formulation of Bevacizumab by Outlook Therapeutics.
Company
Pharmaceutical intelligence for Outlook Therapeutics with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.